Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Guardian Pharmacy Services (GRDN) Other financing activities (2023 - 2025)

Historic Other financing activities for Guardian Pharmacy Services (GRDN) over the last 3 years, with Q3 2025 value amounting to $25000.0.

  • Guardian Pharmacy Services' Other financing activities fell 9738.22% to $25000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year increase of 4926.77%. This contributed to the annual value of $4.2 million for FY2024, which is 36760.4% up from last year.
  • According to the latest figures from Q3 2025, Guardian Pharmacy Services' Other financing activities is $25000.0, which was down 9738.22% from $60000.0 recorded in Q2 2025.
  • Guardian Pharmacy Services' Other financing activities' 5-year high stood at $2.0 million during Q4 2024, with a 5-year trough of $25000.0 in Q3 2025.
  • For the 3-year period, Guardian Pharmacy Services' Other financing activities averaged around $765875.0, with its median value being $612500.0 (2023).
  • As far as peak fluctuations go, Guardian Pharmacy Services' Other financing activities skyrocketed by 48404.56% in 2024, and later plummeted by 9738.22% in 2025.
  • Over the past 3 years, Guardian Pharmacy Services' Other financing activities (Quarter) stood at $351000.0 in 2023, then surged by 484.05% to $2.0 million in 2024, then plummeted by 98.78% to $25000.0 in 2025.
  • Its last three reported values are $25000.0 in Q3 2025, $60000.0 for Q2 2025, and $1.5 million during Q1 2025.